Integral Health Asset Management’s Nurix Therapeutics NRIX Stock Holding History

Integral Health Asset Management’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-700,000	Closed	-$10.8M	–	109
2026 Q1	$10.8M	Buy	700,000 +400,000	+133%	+$6.63M	0.52%	54
2025 Q4	$5.69M	Sell	300,000 -50,000	-14%	-$718K	0.28%	68
2025 Q3	$3.23M	Buy	350,000 +40,000	+13%	+$415K	0.22%	73
2025 Q2	$3.53M	Buy	310,000 +35,000	+13%	+$378K	0.32%	64
2025 Q1	$3.27M	Buy	275,000 +25,000	+10%	+$418K	0.35%	67
2024 Q4	$4.71M	Buy	250,000 +50,000	+25%	+$1.15M	0.4%	64
2024 Q3	$4.49M	Buy	200,000 +50,000	+33%	+$1.13M	0.51%	48
2024 Q2	$3.13M	Buy	+150,000	New	+$2.34M	0.3%	67

Other funds holding NRIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Integral Health Asset Management's NRIX Position: Q2 2026 in Review

Integral Health Asset Management sold out of Nurix Therapeutics (NRIX) in Q2 2026, closing a stake of 700,000 shares — an estimated $10.8M sold.

Integral Health Asset Management first reported a position in NRIX in Q2 2024 and held it in 8 quarters. The position peaked at $10.8M in Q1 2026. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

Integral Health Asset Management reported no remaining Nurix Therapeutics position as of Q2 2026 after selling out during the quarter.
Integral Health Asset Management sold 700,000 Nurix Therapeutics shares in Q2 2026, an estimated $10.8M.
Integral Health Asset Management first reported a position in Nurix Therapeutics in Q2 2024 and held it in 8 quarters.
Integral Health Asset Management's Nurix Therapeutics position peaked at $10.8M in Q1 2026.
211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Integral Health Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.